Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy regimen consisting of fruquintinib, a highly selective small-molecule tyrosine kinase inhibitor of VEGFR-1, 2, and 3, and a PD-1 checkpoint inhibitor (such as nivolumab, sintilimab, or tislelizumab). This combination is being investigated as a first-line maintenance therapy for patients with advanced HER-2 negative gastric cancer or gastroesophageal junction adenocarcinoma who have not progressed following initial chemo-immunotherapy. The rationale for this combination lies in the synergistic potential of antiangiogenic agents to normalize tumor vasculature and modulate the tumor microenvironment, thereby enhancing the antitumor activity of PD-1 blockade. Fruquintinib was developed by HUTCHMED, while the PD-1 inhibitors are developed by various companies including Bristol Myers Squibb, Innovent Biologics, and BeiGene.
- Brand names
- ElunateOpdivoTyvytTevimbra
- Other names
- Fruquintinib plus PD-1 inhibitor
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on fruquintinib + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + PD-1 inhibitor.